alexa ETEC Vaccine between Reality and Expectations | Open Access Journals
ISSN: 2157-7560
Journal of Vaccines & Vaccination
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

ETEC Vaccine between Reality and Expectations

Nasr-Eldin Mohamed M. Aref*

Department of Animal Medicine, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt

*Corresponding Author:
Nasr-Eldin Mohamed M. Aref
Department of Animal Medicine
Faculty of Veterinary Medicine
Assiut University, Assiut-71526, Egypt
Tel: +0160024252
E-mail: [email protected]

Received date: August 28, 2012; Accepted date: September 04, 2012; Published date: September 08, 2012

Citation: Aref NEMM (2012) ETEC Vaccine between Reality and Expectations. J Vaccines Vaccin 3:e110. doi:10.4172/2157-7560.1000e110

Copyright: © 2012 Aref NEMM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Vaccines & Vaccination

Strains of enterotoxigenic Escherichia coli (ETEC) have been recognized as the first leading cause of neonatal diarrhea and the second major cause of infant mortality in developing countries [1-2]. Insufficient data exist, but conservative estimates suggest that ETEC strains are incriminated as the cause of 280-400 million diarrheal episodes per year in children under 5 years of age, resulting in 300,000 to 500,000 deaths. ETEC is also the most common cause of travelers’ diarrhea, being responsible for one-third to one-half of all diarrheal episodes in travelers to Africa, Asia and Latin America [3].

The main hallmarks of this type of bacteria are expression of more than one colonization factors (CFs) used for attachment to host intestinal cells and elaboration of one or more enterotoxins [4]. To date, 25 distinct CFs have been identified [5] and 2 major enterotoxins, the heat-stable (ST) and heat-labile (LT) enterotoxins. Both toxins elicit net secretion of ions and water, resulting in profuse watery diarrhea and potentially fatal dehydration.

The antigenic diversity of these strains (enterotoxins/colonization factors (CFs) combinations) accounts for the high prevalence of ETEC-induced diarrhea in the endemic areas and poses challenges for development of a broad-spectrum ETEC vaccine [5]. Currently, there is no licensed vaccine that confers a broad protection against the heterogeneous array of ETEC strains although recent donor investments from the USA (Bill & Melinda Gates Foundation) and Europe (STOPENTERICS, GLOBVACEntVac) have reinvigorated the efforts on vaccine development [6].

A variety of strategies have been pursued in attempts to develop a broad spectrum ETEC vaccine. Prior studies suggest that liveattenuated or inactivated whole-cell vaccines may be viable options if safety and immunogenicity issues can be overcome. Promising data in this regard were reported from two recently completed Phase IIb immunization challenge studies evaluating a new live, whole-cell vaccine (ACE527) comprised of three attenuated ETEC strains [7]. Results from these studies were promising and PATH is planning to conduct further testing of ACE527 with and without co-administered adjuvant prior to entering a descending-age study in an ETEC-endemic country. The study is expected to launch in 2013.

Inactivated whole-cell ETEC vaccines also showed impressive progress. An inactivated ETEC vaccine composed of four ETEC strains engineered to overexpress CFA/I, CS3, CS5 and CS6 and supplemented with a LTB–CTB hybrid toxoid (Jan Holmgren, Goteborg University, Goteborg, Sweden) induced strong intestinal and serum antibody responses to these antigens in a mouse model, which could be significantly improved by administration with the double mutant heatlabile toxin mucosal adjuvant. In a human Phase I trial, an inactivated, overexpressing CFA/I strain and the new hybrid toxoid induced stronger intestinal (fecal IgA) or intestinal-derived antibody responses to CFA/I and LTB than the first-generation ETEC-inactivated vaccine.

While secondary analysis of a Phase II LT-patch transcutaneous immunization study demonstrated significant protection against ETEC-LT strains (ELT206) (Larry Ellingsworth, Intercell, MD, USA), the Phase III trials’ primary endpoints (ELT301), reduction of incidence of all types of ETEC (defined as cases in which ETEC LT, LT/ST or ST toxins are detected in diarrheal stool samples) and/or all cause diarrhea (secondary endpoints) comparing the vaccine groups with the placebo group, were not met.

Also, a prototype conserved ETEC tip-adhesin (FTA)-based vaccine, delivered by transcutaneous immunization and intradermal routes was well tolerated and induced impressive levels of anti-tip adhesin ELISA and functional antibodies (Stephen Savarino, Naval Medical Research Center, MD, USA). Results from ongoing nonhuman primate studies demonstrated that intradermal immunization with FTA and mLT induced significant protection (84%) against challenge with a fully virulent ETEC strain [6].

While targeting CFs antigens in ETEC vaccine development show very promising results, it should be kept in mind that these CFs antigens may undergo an antigenic mutations causing failure of CF-based ETEC vaccines. Additionally new emerging ETEC strains could hit under certain circumstances. Therefore looking for a conservative antigenic determinant in ETEC should be of high priorities. Selecting ST as a candidate for constructing a broad spectrum ETEC vaccine has been rationalized by its conservative structure in all ETEC strains, however this approach has been challenged by its haptenic and toxicity nature [5]. Therefore research efforts should be directed to overcome these challenges for constructing a non-toxigenic version of immunogenic ST. Such version is often referred to as an ST toxoid. The application of advanced genomic, proteomic and nanotechnologies as well as new vaccine delivery routes will pave the way to accomplish this goal.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 11573
  • [From(publication date):
    September-2012 - Sep 25, 2017]
  • Breakdown by view type
  • HTML page views : 7797
  • PDF downloads :3776
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords